Evommune Q3 2026 Results: Strong Pipeline, Capital Raise, & Growth Outlook
Evommune’s Q3 2026 results reveal strong pipeline progress for atopic dermatitis and a new small‑molecule licensing deal, backed by solid cash flow and 2027 Phase 1/2 plans.
2 minutes to read
